Tesamorelin
12mg vial.
Tesamorelin is a GHRH analog. EGRIFTA WR has a narrow FDA-approved indication for reducing excess abdominal fat in adults with HIV-associated lipodystrophy and is not indicated for weight-loss management.
Interested in Tesamorelin?
Our medical team will evaluate if this medication is right for you during your consultation.
Dosage & Administration
Daily subcutaneous injections for 12-26 weeks (extendable to 52 weeks with monitoring). Follow the instructions for the exact prescribed product.
Important: Like any prescribed medication, dosing varies from person to person. Always follow the dosage prescribed by your healthcare provider. Optimize 360 personalizes every protocol based on your labs, symptoms, and goals.
Side Effects
- Injection Site Reactions: Redness, itching, or bumps at the injection site may occur.
- Joint Pain: Related to growth hormone effects.
- Headache: Mild.
- Swelling: Mild fluid retention possible.
Why Choose Optimize 360 for Tesamorelin
- Prescribed and monitored by Dr. Steve Farmer — 30+ years in hormone medicine
- Comprehensive lab work before prescribing — we never guess
- Sourced from licensed U.S. compounding pharmacies
- Transparent pricing — the price above is what you pay, no hidden fees
- Telehealth available nationwide — medications shipped to your door
- Unlimited messaging with your provider throughout treatment
Get Started Today
No memberships. No referral needed. Schedule your consultation and we'll take it from there.
How Tesamorelin Works
Tesamorelin is a growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary gland to produce and release growth hormone. It contains the full 44-amino-acid GHRH sequence with an additional hexenoyl group. EGRIFTA WR is FDA approved for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy; its label says it is not indicated for weight-loss management. Structure alone does not prove superiority over another GHRH analog.
Benefits & Clinical Evidence
Tesamorelin has randomized placebo-controlled evidence in adults with HIV-associated lipodystrophy and excess abdominal fat. Those studies support the labeled population and should not be treated as direct evidence for sermorelin or as proof of the same benefit-risk balance for general weight loss, anti-aging, recovery, or longevity.
Who Is a Good Candidate?
Suitability depends on the diagnosis, exact product, approved or off-label use, health history, alternatives, and monitoring plan. Evidence from adults with HIV-associated lipodystrophy should not be generalized automatically to another population or treatment goal.
What to Expect: Treatment Timeline
Weeks 1-4: Improved sleep quality and subtle energy improvements. Months 1-3: Measurable increases in IGF-1 levels, early body composition changes, improved recovery. Months 3-6: Significant reduction in visceral abdominal fat (typically 15-18%), improved waist circumference, visible body composition improvements. Tesamorelin is injected subcutaneously once daily, typically before bedtime. Treatment courses usually run 3-6 months with lab monitoring of IGF-1 and metabolic markers. Available at Optimize 360 from $262.50/vial.
Side Effects & Safety
Common side effects include injection site reactions (redness, itching, swelling), joint pain, and peripheral edema — similar to other GH-stimulating therapies. These are generally mild and often resolve with continued use. Because tesamorelin stimulates natural GH production (rather than replacing it), the risk of GH excess is modulated by the body's own feedback mechanisms. Patients with active cancer should not use GH-stimulating therapies. Regular monitoring of IGF-1, fasting glucose, and HbA1c is recommended, as GH can affect insulin sensitivity.
Frequently Asked Questions
A: They share the GHRH pathway but differ in structure, regulatory history, studied populations, and product-specific safety information. No direct human head-to-head trial was identified in our September 2026 review. Read the full tesamorelin versus sermorelin comparison.
A: Studies show that visceral fat tends to gradually reaccumulate after stopping tesamorelin, though the rate varies by individual. Maintaining results long-term typically requires ongoing therapy, lifestyle optimization (diet and exercise), or periodic treatment cycles. Your provider will help you develop a sustainable plan.
A: EGRIFTA WR has a specific FDA-approved indication for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Its label says it is not indicated for weight-loss management. Ask the prescribing clinician to identify the exact product and whether the proposed use is within its approved labeling or off label.
Also Available